Status:
COMPLETED
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.
Eligibility Criteria
Inclusion
- Adults with active rheumatoid arthritis for greater than 6 months and evidence of inflammation.
Exclusion
- Subjects who have conditions precluding the use of cytokine inhibitors or subjects who require DMARDs other than hydroxychloroquine or sulfasalazine are excluded.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00205478
Start Date
June 1 2005
End Date
February 1 2006
Last Update
December 7 2007
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University - Sofia
Sofia, Bulgaria
2
Military Medical Academy - Sofia
Sofia, Bulgaria
3
Transport Hospital
Sofia, Bulgaria
4
MBAL "Stara Zagora" EAD
Stara Zagora, Bulgaria